HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced that the Centers for Medicare & Medicaid Services (CMS) will maintain and increase reimbursement for excimer laser procedures through 2026, while preparing to broaden eligible conditions under new CPT® code definitions effective January 1, 2027.
In its CY 2026 Medicare Physician Fee Schedule Final Rule, CMS reaffirmed the excimer laser as a well-established treatment for psoriasis and other dermatologic disorders. The agency confirmed continued coverage under CPT codes 96920, 96921, and 96922, along with an approximate 3.5% increase in reimbursement rates for 2026. CMS also noted that these codes will remain exclusive to excimer laser procedures until updated descriptors take effect in 2027.
Beginning in 2027, the revised code language—approved by the American Medical Association’s CPT Editorial Panel—will expand the excimer laser’s recognized use to include inflammatory and autoimmune skin conditions such as vitiligo, atopic dermatitis, and alopecia areata. CMS will review extensive clinical and cost-effectiveness data submitted by STRATA and other stakeholders as part of next year’s rulemaking process.
Dr. Dolev Rafaeli, STRATA’s President and CEO, said the CMS decision represents an important milestone for the company’s long-term growth strategy. He noted that the ruling provides confidence in reimbursement stability, supports STRATA’s network of more than 840 partner clinics, and strengthens its efforts to expand excimer laser adoption across immune-mediated skin diseases.
The ruling provides STRATA with greater regulatory certainty as it works to expand the use of excimer laser technology across immune-mediated skin diseases. The company plans to continue collaborating with commercial insurers, healthcare providers, and patient advocates to maintain ethical billing practices and ensure access to proven, non-systemic therapies for patients nationwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.